SCHEDULE: FMR LLC Boosts 10x Genomics Stake to 8.8%

FMR LLC and Abigail P. Johnson have reported an 8.8% beneficial ownership stake in 10x Genomics, Inc.'s Class A Common Stock as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 9,839,175.62 shares of 10x Genomics, Inc. Class A Common Stock.
• This represents 8.8% of the Class A Common Stock outstanding.
• The reported ownership includes 892,772 shares of Class B Common Stock, which are convertible into Class A Common Stock on a 1:1 basis.
• These Class B shares constitute 7.4144% of the outstanding Class B Common Stock.
• Assuming the conversion of all outstanding Class B shares into Class A Common Stock, the reported beneficial ownership would represent 7.9906% of the total Class A Common Stock.
• FMR LLC holds sole voting power over 9,806,070.00 shares and sole dispositive power over 9,839,175.62 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of 10x Genomics, Inc.

Sentiment

Score: 7

Explanation: The filing indicates a significant and stable institutional ownership by FMR LLC and Abigail P. Johnson, suggesting confidence in the company's long-term prospects. The stated purpose of holding shares in the ordinary course of business, without intent to influence control, is generally viewed positively by the market.

Positives

• A major institutional investor, FMR LLC, and its CEO, Abigail P. Johnson, hold a significant 8.8% stake, indicating confidence in 10x Genomics.
• The acquisition is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investment in 10x Genomics, a company operating in the biotechnology and life sciences sector, known for its genomics research tools. Such a substantial stake by a major asset manager like FMR LLC can signal long-term confidence in the company's market position and growth prospects within the rapidly evolving genomics industry.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by FMR LLC as a positive signal, potentially increasing investor confidence and stability in the stock.
• The filing clarifies the ownership structure and control within FMR LLC, which is relevant for understanding the ultimate beneficial owners of the shares.

Key Dates

Recommendation

The filing indicates a significant and stable institutional ownership by FMR LLC, a major asset manager, which is generally a positive signal for the company's long-term prospects. However, a Schedule 13G filing primarily reports ownership and does not provide new financial performance data, strategic updates, or operational insights that would warrant a 'buy' or 'sell' recommendation. The current information suggests a stable investment, supporting a 'hold' position for existing investors, while new investors would need to consider broader financial and market data beyond this ownership report.

Keywords

10x Genomics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Class A Common Stock, Institutional Investment, Biotechnology, Life Sciences